Glaukos Corporation (GKOS)
| Market Cap | 10.12B +113.3% |
| Revenue (ttm) | 612.84M +41.5% |
| Net Income | -188.05M |
| EPS | -3.25 |
| Shares Out | 58.96M |
| PE Ratio | n/a |
| Forward PE | 1,658.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 621,747 |
| Open | 169.75 |
| Previous Close | 171.09 |
| Day's Range | 167.97 - 172.76 |
| 52-Week Range | 73.16 - 191.62 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 197.15 (+14.84%) |
| Earnings Date | Oct 28, 2026 |
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ... [Read more]
Financial Performance
In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $197.15, which is an increase of 14.84% from the latest price.
News
Glaukos Transcript: Wells Fargo 21st Annual Healthcare Conference
Epioxa's commercial launch is progressing, with payer access expanding and Photrexa sunset. iDose growth continues, though guidance is cautious due to seasonality and reimbursement uncertainty. The pipeline is robust, with new device launches and pivotal trial data expected in the next 12–18 months.
Glaukos price target raised to $202 from $193 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $202 from $193 and keeps a Buy rating on the shares as part of a broader research note updating the…
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $225 from $188 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos (GKOS) to $225 from $188 and keeps a Buy rating on the shares. The firm is more optimistic on…
Glaukos Slides: Investor presentation
Glaukos has posted slides in relation to its latest quarterly earnings report, which was published on July 31, 2026.
Glaukos price target raised to $195 from $168 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Glaukos (GKOS) to $195 from $168 and keeps a Buy rating on the shares after a beat and raise Q2 report. Management…
Glaukos price target raised to $172 from $150 at UBS
UBS raised the firm’s price target on Glaukos (GKOS) to $172 from $150 and keeps a Neutral rating on the shares.
Glaukos price target raised to $193 from $164 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $193 from $164 and keeps a Buy rating on the shares. The company delivered “above and beyond” Q2, with iDose…
Glaukos price target raised to $201 from $150 at Needham
Needham analyst David Saxon raised the firm’s price target on Glaukos (GKOS) to $201 from $150 and keeps a Buy rating on the shares after its better-than-expected Q2 results and…
Glaukos price target raised to $190 from $175 at Stifel
Stifel raised the firm’s price target on Glaukos (GKOS) to $190 from $175 and keeps a Buy rating on the shares.
Glaukos price target raised to $195 from $165 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Glaukos (GKOS) to $195 from $165 and keeps an Overweight rating on the shares. The firm notes Glaukos posted…
Glaukos price target raised to $188 from $175 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos (GKOS) to $188 from $175 and keeps a Buy rating on the shares.
Glaukos price target raised to $178 from $138 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Glaukos (GKOS) to $178 from $138 and keeps an Overweight rating on the shares. The firm notes the company…
Glaukos Earnings Call Transcript: Q2 2026
Record Q2 net sales rose 50% year-over-year, driven by strong U.S. glaucoma and Epioxa launches. Full-year 2026 guidance was raised to $680M–$700M, with robust growth expected across all segments and continued investment in commercial and R&D priorities.
Glaukos Earnings release: Q2 2026
Glaukos released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Glaukos Quarterly report: Q2 2026
Glaukos has published its Q2 2026 quarterly earnings report on July 29, 2026.
Glaukos raises FY26 revenue view to $680M-$700M, consensus $629.98M
Previous view $620M-$635M.
Glaukos reports Q2 adjusted EPS (14c), consensus (21c)
Reports Q2 revenue $185.6M, consensus $150.91M. “Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well posi...
Glaukos Announces Second Quarter 2026 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos assumed with Neutral from Buy at UBS
UBS downgraded Glaukos (GKOS) to Neutral from Buy with a $150 price target after assuming coverage of the name. The firm cites elevated expectations for the downgrade, saying the shares…
Glaukos completes patient enrollment in 510k study for PRESERFLO
Glaukos (GKOS) announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO MicroShunt in adult patients with primary open-angle glaucoma, POAG, who failed ...
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $175 from $170 at Stifel
Stifel raised the firm’s price target on Glaukos (GKOS) to $175 from $170 and keeps a Buy rating on the shares. Following iDose survey work, the firm sees probability-weighted 2027…
Glaukos price target raised to $180 from $160 at Truist
Truist raised the firm’s price target on Glaukos (GKOS) to $180 from $160 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Glaukos price target raised to $164 from $162 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $164 from $162 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…